Founded in Carlsbad, United States, Amicrobe is dedicated to developing advanced biomaterials aimed at preventing and treating infections. The company's core mission is to create safer, more effective solutions for infection control, leveraging the intersection of biotechnology and materials science. Amicrobe's flagship technology, Amicidins™, is engineered to offer versatile physical properties and potent antimicrobial activity, targeting applications in surgery and trauma care. Their innovative approach not only aims to improve patient outcomes but also emphasizes environmental sustainability.

Amicrobe has garnered support from notable entities such as the U.S. Department of Defense, the Combatting Antibiotic Resistance Biopharmaceutical Accelerator (CARB-X), and the U.K. Global AMR Innovation Fund. These affiliations underscore the company's significant contributions to combating antibiotic resistance and enhancing infection prevention strategies. By advancing their product pipeline and securing strategic partnerships, Amicrobe has positioned itself as a key player in the field of infection control, making a substantial impact on public health and safety.